Clinical Trials Details

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Brest Cancer (SCARLET), A Randomized Phase III Study

IRB Protocol Number

SWOG 2212

Clinical Trial Categories

• Breast Cancer

How to Participate

Eligibility: 

Men or women ages 18 and older, with diagnosis of triple negative breast cancer (ER negative, PR negative, HER2 negative) clinical stage T2-T4, N0, M0 or T1-T3, N1-2, M0, without any prior treatment or surgery for current breast cancer.